137 related articles for article (PubMed ID: 38573202)
1. Neoadjuvant immune checkpoint blockade enhances local and systemic tumor immunity in head and neck cancer.
Zhao Y; Wucherpfennig KW
Curr Opin Oncol; 2024 May; 36(3):136-142. PubMed ID: 38573202
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immune checkpoint blockade triggers persistent and systemic T
Blomberg OS; Kos K; Spagnuolo L; Isaeva OI; Garner H; Wellenstein MD; Bakker N; Duits DEM; Kersten K; Klarenbeek S; Hau CS; Kaldenbach D; Raeven EAM; Vrijland K; Kok M; de Visser KE
Oncoimmunology; 2023; 12(1):2201147. PubMed ID: 37089449
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer.
Sanber K; Rosner S; Forde PM; Marrone KA
BioDrugs; 2023 Nov; 37(6):775-791. PubMed ID: 37603233
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
[TBL] [Abstract][Full Text] [Related]
6. [
Vos JL; Zuur CL; Smit LA; de Boer JP; Al-Mamgani A; van den Brekel MWM; Haanen JBAG; Vogel WV
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2010-2022. PubMed ID: 34957526
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy.
Topalian SL; Forde PM; Emens LA; Yarchoan M; Smith KN; Pardoll DM
Cancer Cell; 2023 Sep; 41(9):1551-1566. PubMed ID: 37595586
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral CD103
Ren S; Lan T; Wu F; Chen S; Jiang X; Huo C; Li Z; Xie S; Wu D; Wang R; Li Y; Qiu L; Huang G; Li S; Wang X; Cen M; Cai T; Lin Z; Li J; Li B
Cancer Commun (Lond); 2023 Oct; 43(10):1143-1163. PubMed ID: 37658605
[TBL] [Abstract][Full Text] [Related]
9. Progenitor-like exhausted SPRY1
Liu Z; Zhang Y; Ma N; Yang Y; Ma Y; Wang F; Wang Y; Wei J; Chen H; Tartarone A; Velotta JB; Dayyani F; Gabriel E; Wakefield CJ; Kidane B; Carbonelli C; Long L; Liu Z; Su J; Li Z
Cancer Cell; 2023 Nov; 41(11):1852-1870.e9. PubMed ID: 37832554
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders.
Zhou L; Zeng Z; Egloff AM; Zhang F; Guo F; Campbell KM; Du P; Fu J; Zolkind P; Ma X; Zhang Z; Zhang Y; Wang X; Gu S; Riley R; Nakahori Y; Keegan J; Haddad R; Schoenfeld JD; Griffith O; Manguso RT; Lederer JA; Liu XS; Uppaluri R
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058328
[TBL] [Abstract][Full Text] [Related]
11. Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence.
Vaidya P; Cohen EEW
Clin Cancer Res; 2024 Apr; 30(7):1232-1239. PubMed ID: 37955563
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant PD-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma.
Huang S; Xiong C; Tan K
Am J Otolaryngol; 2023; 44(6):103985. PubMed ID: 37442083
[TBL] [Abstract][Full Text] [Related]
13. Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade.
Wang W; Lozar T; Golfinos AE; Lee D; Gronski E; Ward-Shaw E; Hayes M; Bruce JY; Kimple RJ; Hu R; Harari PM; Xu J; Keske A; Sondel PM; Fitzpatrick MB; Dinh HQ; Lambert PF
Clin Cancer Res; 2022 Jul; 28(13):2953-2968. PubMed ID: 35621713
[TBL] [Abstract][Full Text] [Related]
14. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
Hanna GJ; Adkins DR; Zolkind P; Uppaluri R
Oral Oncol; 2017 Oct; 73():65-69. PubMed ID: 28939078
[TBL] [Abstract][Full Text] [Related]
15. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.
Luoma AM; Suo S; Wang Y; Gunasti L; Porter CBM; Nabilsi N; Tadros J; Ferretti AP; Liao S; Gurer C; Chen YH; Criscitiello S; Ricker CA; Dionne D; Rozenblatt-Rosen O; Uppaluri R; Haddad RI; Ashenberg O; Regev A; Van Allen EM; MacBeath G; Schoenfeld JD; Wucherpfennig KW
Cell; 2022 Aug; 185(16):2918-2935.e29. PubMed ID: 35803260
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
Vos JL; Elbers JBW; Krijgsman O; Traets JJH; Qiao X; van der Leun AM; Lubeck Y; Seignette IM; Smit LA; Willems SM; van den Brekel MWM; Dirven R; Baris Karakullukcu M; Karssemakers L; Klop WMC; Lohuis PJFM; Schreuder WH; Smeele LE; van der Velden LA; Bing Tan I; Onderwater S; Jasperse B; Vogel WV; Al-Mamgani A; Keijser A; van der Noort V; Broeks A; Hooijberg E; Peeper DS; Schumacher TN; Blank CU; de Boer JP; Haanen JBAG; Zuur CL
Nat Commun; 2021 Dec; 12(1):7348. PubMed ID: 34937871
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
18. Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.
Parekh J; Parikh K; Reuss JE; Friedlaender A; Addeo A
Curr Oncol Rep; 2023 Aug; 25(8):913-922. PubMed ID: 37249833
[TBL] [Abstract][Full Text] [Related]
19. Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma.
Sun J; Fang G; Zuo Z; Yu X; Xue L; Li C; Li S
Technol Cancer Res Treat; 2021; 20():15330338211045823. PubMed ID: 34657509
[TBL] [Abstract][Full Text] [Related]
20. CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma.
Hoffmann F; Franzen A; de Vos L; Wuest L; Kulcsár Z; Fietz S; Maas AP; Hollick S; Diop MY; Gabrielpillai J; Vogt T; Kuster P; Zarbl R; Dietrich J; Kristiansen G; Brossart P; Landsberg J; Strieth S; Dietrich D
Clin Epigenetics; 2023 Jul; 15(1):112. PubMed ID: 37415208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]